737 related articles for article (PubMed ID: 19250932)
1. S26948, a new specific peroxisome proliferator activated receptor gamma modulator improved in vivo hepatic insulin sensitivity in 48 h lipid infused rats.
Sohn KA; Cruciani-Guglielmacci C; Kassis N; Clément L; Ouali F; Caüzac M; Lebègue N; Berthelot P; Caignard DH; Pégorier JP; Renard P; Dacquet C; Ktorza A; Magnan C;
Eur J Pharmacol; 2009 Apr; 608(1-3):104-11. PubMed ID: 19250932
[TBL] [Abstract][Full Text] [Related]
2. Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat.
Minoura H; Takeshita S; Yamamoto T; Mabuchi M; Hirosumi J; Takakura S; Kawamura I; Seki J; Manda T; Ita M; Mutoh S
Eur J Pharmacol; 2005 Sep; 519(1-2):182-90. PubMed ID: 16039648
[TBL] [Abstract][Full Text] [Related]
3. FK-614, a selective peroxisome proliferator-activated receptor gamma agonist, improves peripheral glucose utilization while decreasing hepatic insulin extraction in alloxan-induced diabetic dogs.
Uchino H; Kim T; Lam TK; Yoshii H; Klement P; Williams W; Kawamori R; Giacca A
Metabolism; 2005 Sep; 54(9):1250-8. PubMed ID: 16125538
[TBL] [Abstract][Full Text] [Related]
4. Mechanism by which a novel non-thiazolidinedione peroxisome proliferator-activated receptor gamma agonist, FK614, ameliorates insulin resistance in Zucker fatty rats.
Minoura H; Takeshita S; Kimura C; Hirosumi J; Takakura S; Kawamura I; Seki J; Manda T; Mutoh S
Diabetes Obes Metab; 2007 May; 9(3):369-78. PubMed ID: 17391165
[TBL] [Abstract][Full Text] [Related]
5. [Effect of free fatty acid-induced insulin resistance on plasma ghrelin level: an experimental study with rats].
Li L; Yang GY
Zhonghua Yi Xue Za Zhi; 2004 Oct; 84(19):1645-8. PubMed ID: 15569462
[TBL] [Abstract][Full Text] [Related]
6. Adiponectin concentrations increase during acute FFA elevation in humans treated with rosiglitazone.
Krzyzanowska K; Mittermayer F; Krugluger W; Roden M; Schernthaner G; Wolzt M
Horm Metab Res; 2007 Oct; 39(10):769-72. PubMed ID: 17952842
[TBL] [Abstract][Full Text] [Related]
7. Effect of GCP-02, a PPARalpha/gamma dual activator, on glucose and lipid metabolism in insulin-resistant mice.
Wang ZJ; Liu Q; Li PP; Zou CH; Shen ZF
Eur J Pharmacol; 2008 Feb; 580(1-2):277-83. PubMed ID: 18048028
[TBL] [Abstract][Full Text] [Related]
8. Effect of sodium salicylate on oxidative stress and insulin resistance induced by free fatty acids.
He B; Zhao S; Zhang W; Li Y; Han P
Hepatobiliary Pancreat Dis Int; 2010 Feb; 9(1):49-53. PubMed ID: 20133229
[TBL] [Abstract][Full Text] [Related]
9. High-fat- and lipid-induced insulin resistance in rats: the comparison of glucose metabolism, plasma resistin and adiponectin levels.
Li L; Yang G; Li Q; Tang Y; Li K
Ann Nutr Metab; 2006; 50(6):499-505. PubMed ID: 17191023
[TBL] [Abstract][Full Text] [Related]
10. Salicylate prevents hepatic insulin resistance caused by short-term elevation of free fatty acids in vivo.
Park E; Wong V; Guan X; Oprescu AI; Giacca A
J Endocrinol; 2007 Nov; 195(2):323-31. PubMed ID: 17951543
[TBL] [Abstract][Full Text] [Related]
11. Free fatty acid-induced hepatic insulin resistance: a potential role for protein kinase C-delta.
Lam TK; Yoshii H; Haber CA; Bogdanovic E; Lam L; Fantus IG; Giacca A
Am J Physiol Endocrinol Metab; 2002 Oct; 283(4):E682-91. PubMed ID: 12217885
[TBL] [Abstract][Full Text] [Related]
12. 18F9 (4-(3,6-bis (ethoxycarbonyl)-4,5,6,7-tetrahydrothieno (2,3-c) pyridin-2-ylamino)-4-oxobutanoic acid) enhances insulin-mediated glucose uptake in vitro and exhibits antidiabetic activity in vivo in db/db mice.
Anandharajan R; Sayyed SG; Doshi LS; Dixit P; Chandak PG; Dixit AV; Brahma MK; Deshmukh NJ; Gupte R; Damre A; Suthar J; Padigaru M; Sharma SD; Nemmani KV
Metabolism; 2009 Oct; 58(10):1503-16. PubMed ID: 19608207
[TBL] [Abstract][Full Text] [Related]
13. Berberine improves free-fatty-acid-induced insulin resistance in L6 myotubes through inhibiting peroxisome proliferator-activated receptor gamma and fatty acid transferase expressions.
Chen Y; Li Y; Wang Y; Wen Y; Sun C
Metabolism; 2009 Dec; 58(12):1694-702. PubMed ID: 19767038
[TBL] [Abstract][Full Text] [Related]
14. Tissue-specific effects of rosiglitazone and exercise in the treatment of lipid-induced insulin resistance.
Lessard SJ; Rivas DA; Chen ZP; Bonen A; Febbraio MA; Reeder DW; Kemp BE; Yaspelkis BB; Hawley JA
Diabetes; 2007 Jul; 56(7):1856-64. PubMed ID: 17440174
[TBL] [Abstract][Full Text] [Related]
15. Antidiabetic and hypolipidemic potential of DRF 2519--a dual activator of PPAR-alpha and PPAR-gamma.
Chakrabarti R; Misra P; Vikramadithyan RK; Premkumar M; Hiriyan J; Datla SR; Damarla RK; Suresh J; Rajagopalan R
Eur J Pharmacol; 2004 May; 491(2-3):195-206. PubMed ID: 15140637
[TBL] [Abstract][Full Text] [Related]
16. Metabolic action of peroxisome proliferator-activated receptor gamma agonism in rats with exogenous hypercorticosteronemia.
Berthiaume M; Laplante M; Tchernof A; Deshaies Y
Int J Obes (Lond); 2007 Nov; 31(11):1660-70. PubMed ID: 17579631
[TBL] [Abstract][Full Text] [Related]
17. PPARgamma agonist induced cardiac enlargement is associated with reduced fatty acid and increased glucose utilization in myocardium of Wistar rats.
Edgley AJ; Thalén PG; Dahllöf B; Lanne B; Ljung B; Oakes ND
Eur J Pharmacol; 2006 May; 538(1-3):195-206. PubMed ID: 16674938
[TBL] [Abstract][Full Text] [Related]
18. Free fatty acids increase basal hepatic glucose production and induce hepatic insulin resistance at different sites.
Lam TK; van de Werve G; Giacca A
Am J Physiol Endocrinol Metab; 2003 Feb; 284(2):E281-90. PubMed ID: 12531742
[TBL] [Abstract][Full Text] [Related]
19. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats.
Choi KC; Ryu OH; Lee KW; Kim HY; Seo JA; Kim SG; Kim NH; Choi DS; Baik SH; Choi KM
Biochem Biophys Res Commun; 2005 Oct; 336(3):747-53. PubMed ID: 16157299
[TBL] [Abstract][Full Text] [Related]
20. PPARalpha /gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly.
Ye JM; Iglesias MA; Watson DG; Ellis B; Wood L; Jensen PB; Sørensen RV; Larsen PJ; Cooney GJ; Wassermann K; Kraegen EW
Am J Physiol Endocrinol Metab; 2003 Mar; 284(3):E531-40. PubMed ID: 12556350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
